Payers, Medical Journals Could Help Push For Clinical Trial Diversity, Cavazzoni Says

The director of the US FDA’s Center for Drug Evaluation and Research acknowledged that the FDA cannot improve trial diversity alone.

diversity
CDER Director Patrizia Cavazzoni also said the agency must implement diversity requirements without making drug development too difficult. • Source: Shutterstock

The US Food and Drug Administration is preparing to implement new clinical trial diversity requirements, but Center for Drug Evaluation and Research Director Patrizia Cavazzoni believes other stakeholders could help ensure sponsors test new drugs in all relevant populations.

More from Clinical Trials

More from R&D